The Authors Reply:  by Ott, Susan M. et al.
Comments on KDIGO clinical
practice guidelines for
bisphosphonate treatment
of chronic kidney disease
To the Editor: The Kidney International1 published the
KDIGO Clinical Practice Guidelines for the Diagnosis Eval-
uation Prevention Treatment of Chronic Kidney Disease–-
Mineral and Bone Disorder in chronic kidney disease (CKD).
The information on the potential use of osteoporotic anti-
fracture agents, particularly bisphosphonates (BP), is crucial
but poses a few questions:
1. BP therapy is not approved in CKD (glomerular
filtration rateo30–35ml/min); BP may only be used
on the doctor’s own responsibility.
2. Fracture risk assessment in CKD is unestimated.
FRAX and certain qualitative methods used in osteo-
porosis are not approved for CKD.
3. Bone biopsy, excluding adynamic bone disease, is a
sine qua non in BP therapy. It may suggest the drug
use in osteomalacia, and mild and mixed renal osteo-
dystrophy, which raises doubts.
4. BP dosage in CKD is not established. Should it be
reduced? BP removal on hemodialysis, with a simul-
taneous decrease in urine excretion, may suggest no
need for dose reduction.
5. The optimal BP form is unknown. Weekly dosing
with a possible earlier discontinuation seems to be
safer than long-acting drugs.
6. How to assess the BP efficacy in CKD? Are
bone biopsy, DXA (of which skeletal part?), bone
metabolism markers (formation, resorption, or both)
useful?
7. How long is the safe BP regimen? Can the osteo-
porosis experience be used in CKD?
Without addressing the issues, we are not ready to use BP
or other antifracture agents in CKD patients.
1. KDIGO Clinical Practice Guidelines for the Diagnosis Evaluation Prevention
Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD).
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The Authors Reply: Dr Przedlacki1 has made several
statements about bisphosphonate use in patients with chronic
kidney disease (CKD) stages 4–5. His comments serve to
emphasize points made in the Kidney Disease-Improving
Global Outcomes guideline,2 which stated that ‘The Work
Group could therefore not recommend the routine use of
these agents, especially in light of safety concernsy’ The
guideline did not recommend speciﬁc dosing of bisphos-
phonates but did state that the pharmacodynamics of these
drugs in CKD should be better deﬁned. In individuals with
normal renal function the drugs remain in the blood for about
an hour after an intravenous dose, after which they are partly
cleared by the kidneys and partly deposited in the skeleton,
with a half-life in bone greater than 10 years. However,
the relative contribution of these two processes to overall
plasma elimination differs signiﬁcantly among bisphospho-
nates.3 Furthermore, the optimal dosing and duration
of use of bisphosphonates has not yet been determined in
patients with osteoporosis even when they have normal renal
function.
Patients with CKD–mineral and bone disorder (CKD-
MBD) have an increased risk of fragility fractures, but we do
not have sufﬁcient information for optimal risk assessment
and treatment. Bisphosphonates could potentially help some
patients and excess harm has not been reported in patients
with CKD-MBD; therefore the working group did not state
these drugs must be avoided. However, they should be used
cautiously and only after careful characterization of the
underlying type of bone disease. We are hoping that in the
future, clinical studies will answer some of the questions
posed by Dr Przedlacki.
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